Cargando…

Independent Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor–Positive, Early Breast Cancer

BACKGROUND: EarlyR gene signature in estrogen receptor–positive (ER+) breast cancer is computed from the expression values of ESPL1, SPAG5, MKI67, PLK1, and PGR. EarlyR has been validated in multiple cohorts profiled using microarrays. This study sought to verify the prognostic features of EarlyR in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buechler, Steven A, Gray, Kathryn P, Gökmen-Polar, Yesim, Willis, Scooter, Thürlimann, Beat, Kammler, Rosita, Viale, Giuseppe, Leyland-Jones, Brian, Badve, Sunil S, Regan, Meredith M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049990/ https://www.ncbi.nlm.nih.gov/pubmed/32337480 http://dx.doi.org/10.1093/jncics/pkz051

Ejemplares similares

Interpreting breast international group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer
por: Regan, Meredith M, et al.
Publicado: (2011)

Upregulation of HSF1 in estrogen receptor positive breast cancer
por: Gökmen-Polar, Yesim, et al.
Publicado: (2016)

Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1–98
por: Kensler, Kevin H., et al.
Publicado: (2019)

Is conservative management of ductal carcinoma in situ risky?
por: Zheng, Lan, et al.
Publicado: (2022)

Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98
por: Koeberle, Dieter, et al.
Publicado: (2007)

Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98
por: Koeberle, Dieter, et al.
Publicado: (2007)

CIBERSORT analysis of TCGA and METABRIC identifies subgroups with better outcomes in triple negative breast cancer
por: Craven, Kelly E., et al.
Publicado: (2021)

WITHDRAWN: Analysis of ‘earlyR’ epidemic model and time series model for prediction of COVID-19 registered cases
por: Kanagarathinam, Karthick, et al.
Publicado: (2020)

ColoType: a forty gene signature for consensus molecular subtyping of colorectal cancer tumors using whole-genome assay or targeted RNA-sequencing
por: Buechler, Steven A., et al.
Publicado: (2020)

Prognostic Impact of HOTAIR Expression is Restricted to ER-Negative Breast Cancers
por: Gökmen-Polar, Yesim, et al.
Publicado: (2015)

Thymic Carcinomas and Second Malignancies: A Single-Center Review
por: Badve, Sunil S., et al.
Publicado: (2021)

Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98
por: Alkner, S., et al.
Publicado: (2017)

Three-dimensional imaging and quantitative analysis in CLARITY processed breast cancer tissues
por: Chen, Yi, et al.
Publicado: (2019)

Women Commencing Anastrozole, Letrozole or Tamoxifen for Early Breast Cancer: The Impact of Comorbidity and Demographics on Initial Choice
por: Kemp, Anna, et al.
Publicado: (2014)

The early days of letrozole
por: Bhatnagar, Ajay S.
Publicado: (2007)

The early days of letrozole
por: Bhatnagar, Ajay S.
Publicado: (2008)

Efficacy, Safety, and Prognosis of Sequential Therapy with Tamoxifen and Letrozole versus Letrozole Monotherapy for Breast Carcinoma
por: Lu, Xinli, et al.
Publicado: (2022)

Retracted: Efficacy, Safety, and Prognosis of Sequential Therapy with Tamoxifen and Letrozole versus Letrozole Monotherapy for Breast Carcinoma
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

Endometrial Surveillance in Tamoxifen and Letrozole Treated Breast Cancer Patients
por: AlZaabi, Adhari, et al.
Publicado: (2021)

Influence of the anti‐oestrogens tamoxifen and letrozole on thyroid function in women with early and advanced breast cancer: A systematic review
por: Marina, Djordje, et al.
Publicado: (2022)

Assessment of Quality of Life and Safety in Postmenopausal Breast Cancer Patients Receiving Letrozole as an Early Adjuvant Treatment
por: Jung, Yongsik, et al.
Publicado: (2018)

Quantitative phosphoproteomic analysis identifies novel functional pathways of tumor suppressor DLC1 in estrogen receptor positive breast cancer
por: Gökmen-Polar, Yesim, et al.
Publicado: (2018)

Long-term efficacy and safety of letrozole for the adjuvant treatment of early breast cancer in postmenopausal women: a review
por: Monnier, Alain
Publicado: (2009)

Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue
por: Antonov, Janine, et al.
Publicado: (2010)

The Effect of Undaria pinnatifida Fucoidan on the Pharmacokinetics of Letrozole and Tamoxifen in Patients With Breast Cancer
por: Tocaciu, Shreya, et al.
Publicado: (2016)

Spatially variant immune infiltration scoring in human cancer tissues
por: Allam, Mayar, et al.
Publicado: (2022)

Single cell heterogeneity in ductal carcinoma in situ of breast
por: Gerdes, Michael J, et al.
Publicado: (2017)

Genomic clustering analysis identifies molecular subtypes of thymic epithelial tumors independent of World Health Organization histologic type
por: Padda, Sukhmani K., et al.
Publicado: (2021)

Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients
por: Duchnowska, Renata, et al.
Publicado: (2015)

Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer
por: Aydiner, Adnan, et al.
Publicado: (2008)

Switching to letrozole or exemestane improves hot flushes, mood and quality of life in tamoxifen intolerant women
por: Thomas, R, et al.
Publicado: (2008)

Comparison of the effectiveness of clomiphene citrate, tamoxifen and letrozole in ovulation induction in infertility due to isolated unovulation
por: Seyedoshohadaei, Fariba, et al.
Publicado: (2012)

Comparison of Letrozole Versus Tamoxifen Effects in Clomiphen Citrate Resistant Women with Polycystic Ovarian Syndrome
por: EL-Gharib, Mohamed Nabih, et al.
Publicado: (2015)

Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor–Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5
por: Dowsett, Mitch, et al.
Publicado: (2018)

Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole
por: Lunardi, G., et al.
Publicado: (2012)

Molecular Analysis of Thymoma
por: Badve, Sunil, et al.
Publicado: (2012)

Concomitant use of tamoxifen and endoxifen in postmenopausal early breast cancer: prediction of plasma levels by physiologically-based pharmacokinetic modeling
por: Dickschen, Kristin, et al.
Publicado: (2014)

Adjuvant tamoxifen for early breast cancer.
por: Smith, I.
Publicado: (1988)

Predicting Breast Cancer Events in Ductal Carcinoma In Situ (DCIS) Using Generative Adversarial Network Augmented Deep Learning Model
por: Ghose, Soumya, et al.
Publicado: (2023)

Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR)
por: Kim, Jisun, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_i5ld459ge56d6f3dr8utn8u5g4